Good day everyone and welcome to the Amicus Therapeutics conference call. All lines have been placed on mute to prevent any background noise. After Amicus remarks, there will be a question-and-answer period. (Operator instructions) During this call, Amicus may make various remarks about the company’s future expectations, plans, and prospects that constitute forward-looking statements for purposes of the Safe Harbor Provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those discussed in the company’s most recent Annual Report on Form 10-K and our periodic reports on Form 10-Q. These documents are available from the SEC, the Amicus website, or from our Investor Relations representatives. In addition, any forward-looking statements represent our estimates only as of today and should not be relied upon as representing our estimates as of any subsequent date. While we may like to update forward-looking statements at some time in the future, we specifically disclaim any obligations to do so even if our estimates change. Before we begin, we would ask everyone to go to the Investor Relations section of the company’s website, amicustherapeutics.com, and print out the press release and related financial tables. These will be particularly useful when the company reviews the financial results and reconciliation to non-GAAP financial measures discussed today. And now at this time, I’d like to turn the conference over to Mr. John Crowley, President and CEO of Amicus Therapeutics. Please go ahead sir.

Okay, thank you and good afternoon everyone, and welcome to our third quarter 2008 conference call. I am joined in this call by other members of the executive team here at Amicus, including Matt Patterson, our COO, who will provide an update on our lead lysosomal storage disease clinical program; by Jim Dentzer, our CFO, who will provide an overview of the financial results for the quarter; and also available is David Lockhart, our Chief Scientific Officer, who will be available to participate in the Q&A portion of the call that will follow our formal remarks here. Let me begin by saying that in the third quarter we focused very intensely on continued advancement of our core programs. In our lead program Amigal for Fabry disease, we recalled it in August – we announced successful completion of our Phase – of our end of Phase 2 meeting with the FDA. Since that time, we have continued to make excellent progress in our discussions with both the FDA and the EMEA in Europe in order to further define our global development plan for Phase 3 for Amigal. These discussions are ongoing and we remain optimistic and on track to provide you with an update by the end of the year. Importantly too, I’ll note that where we are in this process is consistent with our expectation and most significantly we continue to expect to begin Phase 3 development for Amigal for February in the first half of 2009. In our Gaucher and Pompe clinical programs, we continue to focus on running our ongoing Phase 2 clinical trial in each of those diseases, and we expect to report the Gaucher Phase 2 data in 2009. Separately in our Pompe program, we continue our pre-clinical work to evaluate the potential for the combination…

Thanks, John, and good afternoon everyone. I’ll start with Amigal for Fabry and just elaborate a little bit on the introduction John has provided. As John mentioned, our focus over the last quarter has been to continue our discussions with both the FDA and the European authorities regarding our global Phase 3 development plan for Amigal. We continue to make excellent progress on these discussions. We’re very encouraged. And as John mentioned, the process has been moving along exactly as we predicted it would. We started these effort months ago now. And as a result, as John mentioned, we’re still on track to initiate Phase 3 development of Amigal in the first half of next year. In addition, in parallel with this regulatory process, we continue to treat patients in the voluntary Phase 2 extension study which we’ve spoken about before but just as a reminder, 26 patients completed the initial Phase 2 protocols; and of these 26 patients, 23 have elected to continue treatment with Amigal in the voluntary extension study, which is a decision we’re highlighting because all these patients have the opportunity to receive enzyme replacement therapy, but stand along with their decisions. They’re choosing to remain in our study so we’re very encouraged by that. And of these 23 patients, all of them have now been on Amigal for more than 1.5 years and in fact eight of them had been on for more than two years and some of them are approaching their third year anniversary, so really an excellent study of continuing data collection for long-term efficacy and safety of Amigal. And so, we expect it will be an ongoing valuable source of data for us. And as mentioned before in previous calls and announcements, we are also using these extension studies as an…

Thanks, Matt, and welcome everyone. I’ll provide a brief summary of the financial results for the third quarter. Overall, we continue to have a strong cash position. In Q3, we used $9 million of cash ending the quarter with approximately $136 million in cash and marketable securities. That compares to $145 million at the end of Q2 and $162 million at the end of 2007. In this difficult market, we continue to manage our cash carefully and expect our current cash, together with expected milestones and reimbursement from Shire, to enable us to fund our operations at least until 2011. As we move to the P&L, I’ll be referring to the tables in our press release, which used the same format as last quarter. Please note that GAAP financials are provided in table one. Table two and table three are a reconciliation of the GAAP and non-GAAP financial results, highlighting charges for three non-cash items, stock-based compensation, preferred stock accretion and changes in fair value for warrants. As with last quarter, the charges for preferred stocks and warrants do not impact the current period as they were converted to common stock in connection with our May 2007 IPO. Total revenue for the third quarter 2008 was $3.7 million, comprising $0.7 million of collaboration revenue on the upfront payment, and $3.0 million in research revenue for the reimbursement of our R&D costs associated with our three lead programs. For the nine months period, total revenue was $10.6 million for the period ended September 30. On a non-GAAP basis, the net loss for the quarter was $6.6 million as compared to $9.2 million for the same period in 2007. The reduction in operating loss was driven primarily by revenue resulting from our collaboration with Shire under which, as many of you know,…

Great. Thanks, Jim. We are now well into the fourth quarter and our focus continues to be on executing against plan to advance and through the clinic each of our three lysosomal storage disease development program. By the end of this year, we plan to have an update for you all on the status of our regulatory discussions for Phase 3 development of Amigal and by Q1 of next year, we expect to announce new data from the Phase 2 extension study with Amigal, and then to initiate the Phase 3 study in the first half of next year, 2009. In Gaucher, we expect to have additional Phase 2 data in the program in 2009 and we also, of course, plan to continue progressing our Pompe program on multiple fronts, both of a monotheraphy and in exploring the potential of a combo therapy there as well. We continue to have strong confidence that our business remains on track and we look forward to executing on some very important milestones over the next six to nine months. And I will add too, as Jim just added more detail to that we are well-positioned financially to continue to execute according to our plan with this business, and we’d like to thank each of you for your continued support. I’ll remind you that in addition to Matt and Jim, David Lockhart is also here and available with the team for questions and answers. And with that, we’d like to open the call to questions so, operator, please go ahead and feel free to open the call.

(Operator instructions) We’ll take our first question from Matt Osborne with Lazard. Matt Osborne – Lazard: Hi, guys. Thanks for taking the question. I have a few questions, if I could start with Matt perhaps. Have you reached an agreement with either of the agencies in the FDA and the EMEA with what would be an acceptable surrogate endpoints for Amigal?

Hey, Matt. No, we haven’t finalized the discussions with either of the FDA or the EMEA, so those continue to be ongoing. And as we mentioned during the call, we expect to be able to provide an update on where exactly we are on that process by the end of the year. And certainly, as we get to that update and then beyond, we’ll keep you totally informed but right now, it’s not complete and we’re on track to provide you an update by the end of the year. Matt Osborne – Lazard: Is there any risk that either group could arrive at a different endpoint? Or do you feel, based on the discussions and comments that you’ve received from both, that they’re moving in the same direction?

I think it’s difficult for me to speak to specifics of those ongoing discussions. I mean, they’re both ongoing now. We are very upbeat about the progress with both. Sure, I mean, it takes some time to get through the process of working with both authorities but we want to get, as we said before, we want to get the perspective from both regions, so we designed the most robust Phase 3 program for global approval and successful marketing of the drug. So we’re all going to do our very best to tie it all together and come up with a plan that makes the most sense for this program. Matt Osborne – Lazard: Great. Then update 23 of those patients in extension study. Have you started to see what the dose optimization? Are you seeing continued stabilization or are these patients starting to improve?

I don’t have a data update for you at this time, Matt, but we’ll give you an update in Q1 as projected earlier; but we are collecting ongoing safety and efficacy data, which does include the clinical measures of disease that we’ve spoken about before, and so we’ll be happy to report on those over time. The focus for the Q1 update will be around those potentially optimized regimens, which means focus on both the safety but also enzyme levels and GL-3 levels, so I think that’s a reasonable expectation for Q1. Matt Osborne – Lazard: Is that like we had the one of the conferences ACMG or –?

A little difficult for me to predict exactly when and, Matt, right now I can’t say any more specifically than Q1, but we’ll do our very best, and of course, we’ll bring it to a scientific forum as soon as we can; but our expectation is at a minimum to provide everyone with a top line update in Q1 by way of press release. Matt Osborne – Lazard: Okay, great. Last question for Jim. Actually, you mentioned, Jim that you have sufficient funds to last until 2011. Does that include the milestone payments from Shire?

Yes. Matt Osborne – Lazard: Great. Thank you.

Next to Greg Wade with Pacific Growth. Greg Wade – Pacific Growth: Good afternoon. Thank you for taking my question. Matt, just with respect to the progress with the two agencies, first question would be what criteria did you pre-specify in terms of your evaluation of the progress you’ll be making there? Help us to understand how you’re measuring that progress. And secondly, in what form do you anticipate updating us by the end of the year on where you at with the two agencies. Thanks.

Sure. Hi Greg. Well, look I think regulatory affair is an occasional and bit of an art form on how things progress and so I wouldn’t say there is a set criteria for establishing a timeframe. You need to work closely with the agency and do what’s most productive and efficient. I think overall in the big picture, we’re making a progress. We expect that when you combine the multiple factors for us which are that we want to work very successfully with FDA. We want to work very successfully with the Europeans. We have a corporate partner at Shire [ph] that’s very involved in this process. And so, I think when you combine all those factors, the timeline we’re working on is really quite reasonable and the most important outcome here is that we got to our Phase 3 program, that we can all have confidence in and we have – and I think the luxury also of doing this in parallel with that Phase 2 extension. We’re interested to see those data and make the best possible selection on those for Phase 3 as well. So I think the timeline all ties together quite well to ensure that we’re giving the Phase 3 program for Amigal the very best chance of success. Greg Wade – Pacific Growth: Great. And how do you expect to update us before the end of the year?

Sorry, I think we’ll – right now our expectation is to issue our press release and it’s possible that we’ll have a Q&A session along with that but honestly that’s just a draft plan. We haven’t finalized that plan at this time. Greg Wade – Pacific Growth: Thanks Matt.

Sure.

We’ll take the next question from Geoff Meacham with JP Morgan. Terry Coyne – JP Morgan: Hey guys. This is Terry in for Jeff today. Thanks for taking the question. Just – you mentioned that you are excited about your discussions with the FDA. I’m just wondering if you can elaborate at all on that. What specifically you’re excited about on those discussions and –?

Yes. Terry of course. This is John. I think what I referred you back to was the announcement that we had this summer about the end of Phase 2 meeting, and that has in it some very important information where it answered some very, very key questions that we have in the three (inaudible) and it told us that the FDA said we’re ready to move to Phase 3 which of course a very important question. It said that we are eligible for accelerated approval and it said that they are not opposed to the use of a surrogate primary endpoint in this study. So we think that’s all good advancement and we’ve commented before and I will reiterate it again here that the tone of the discussion with the agency has been very positive and very helpful. So I think that’s what gives us encouragement. Terry Coyne – JP Morgan: Okay. And then in terms of leaving some of the earlier stage chaperone programs to the clinic, do you think that’s a 2009 thing that we could be expecting or is it something that’s probably a little further out? And then, I’m just wondering how much of that is dictated on the FDA’s – the duration of this Phase 3 Amigal study?

So I think, Terry, you’re talking about the earlier stage, the Parkinson’s and other programs we haven’t disclosed? Terry Coyne – JP Morgan: Exactly.

Right. Yes. We’ve got a number of programs that are underway here at the company and the most advanced of those is the only one that we’ve disclosed largely for competitive reasons and that’s our program in Parkinson’s disease where we’re applying the chaperone technology to that disease of unstable and misfolded proteins. That is a program, as you’re probably aware, that is partially funded by a grant from the Michael J. Fox Foundation. It is a terrific extension of our understanding in human genetic diseases and the use of chaperones. We continue making advancements there on the preclinical work. We’ve released some of that publicly. We would expect to continue to release the preclinical work that we’re doing there into and through 2009, and we don’t yet have any guidance as to when that program could enter the clinic although I would expect to be able to provide more information in 2009. And as you would expect with the other programs, they are earlier in the pipeline and I think as we begin to disclose those programs over the next year or two, that likewise, will be able to provide better guidance about what the timelines looked like for those programs. Terry Coyne – JP Morgan: Okay. So it is not at all predicated upon the potential cause of the Phase 3 studies for Amigal?

No, we’ve already budgeted together with our partners at Shire, the expenses for the Phase 3 studies for Amigal. Terry Coyne – JP Morgan: Okay. Thanks for taking the question.

You’re welcome.

(Operator instructions) We’ll go next to Steve Harr with Morgan Stanley. Steve Harr – Morgan Stanley: Good afternoon. Two questions. First of all, about a year ago, you presented the Phase 2 Amigal data and it was – at the end of it you said would be, you’d go in the FDA and having discussions of moving to Phase 3 and were the same spot a year from now. So what have you learn in the interim, and what are the outstanding questions that you get your hands around before you can go on the Phase 3?

Yes, sure, Steve. This is John, I’ll take that. I actually think we made quite a bit of progress in Fabry over the last of 11 and 10-1/2 months since we presented that first Amigal data. The first part of which was understanding the dosing and that was in series of preclinical studies and pharmacokinetic work that we did together with the folks at Shire, that told us that there maybe more potentially optimize doses. And based on that, we modified all the protocols on all three continents for that program to move all of those patients to the extension study. Essentially, giving us the whole new Phase 2 look in data, but with a population that we already knew quite well, and all of that has been done including moving the patients to those doses and now being able to report that data early in 2009 in the first quarter. So, I think, that’s really good progress there. In addition, we’ve filed all the regulatory paperwork and held discussion now with the regulatory authorities, and just answering those questions, as I alluded [ph] you earlier from – that were out there some pretty significant one about the ability to move forward into Phase 3, about whether a surrogate would be appropriate, whether it would be eligible for accelerated approval. We’ve answered those questions here in the State and we continue to advance the discussion. And I think having a pretty strong idea by the end of this year about what that Phase 3 global program looks like and being able to initiate it first half of 2009. I think that’s pretty good progress in 10-1/2 months. Steve Harr – Morgan Stanley: Is the outstanding question now data related or it’s just a – you need some time to meet with the FDA and actually just dock [ph] the I’s and cross the T’s? Are there still outstanding questions that need to be figured out before you can go forward?

Yes. I think, Steve, I want to be real careful about respecting the confidentiality of the discussions we’re having with FDA and EMEA. So, there were parts of the program that still needs to be resolve. So, I think, a lot of that will be answered over the coming weeks, and hopefully, we’ll be able to provide that update. We’re confident in December. So – and I think we’ve come a long way over the couple of months since we first began the discussion in the summer, and being able to take it to a very significant update in December, I think will be really important for the program. And again, I think, the most important vote of confidence is that we’re very confident that we’ll be able to begin this Fabry Phase 3 in the first half of ’09. Steve Harr – Morgan Stanley: You guys said you have a capital to get through 2011, assuming that you get your milestone payments. Can you walk us through how well your capital will last with that milestone payment? And then, maybe, you could give us some insight into what the events are that you need to see happen to reach this milestone payments to fund the company through 2011?

Sure, Steve, this is Jim. I can answer a little bit of that. Some of it, frankly, I’m going to want it deferred until next quarter. We have a full year behind us, and that we have a more clear picture of what next year looks like. But the bottom line is you’re right. We do need both the reimbursement from Shire, and we need some milestones to get it to that 2011 figure. We do expect that so far all the programs are moving ahead very successfully, and we expect we’re going to be funding all three programs aggressively in 2009 and 2010. I think for now, what I really would like to say is let’s wait until we get the full year results and I can talk more fully about an outlook for 2009 and potentially farther next quarter. Steve Harr – Morgan Stanley: All right, thank you.

Thanks.

Thank you, Steve.

We have a follow up from Matt Osborne with Lazard. Matt Osborne – Lazard: Hi. Thanks for the follow up and, Jim, just a quick question on the patent for 2008. It looks like even at the low end of the range should $40 million assumes a step up in R&D expense for the fourth quarter. Is that safe to assume?

There is a step up. But you’ll also see in the 10-Q that we’re filing today as well, we’ve got some royalties and license payments, some cash payments cutting out in Q4 for a $5.3 million, and there’s also some extra manufacturing that we’re going to do in Q4. So, yes, you’re right. I mean, there is a gradual step up as we’ve said all along in R&D, and that will continue in this 2009 as we further through all three trials, the trials for all three programs. But there are some cash items coming up in Q4 that we’ll push that number into the low end of the range. Matt Osborne – Lazard: Okay, great. Thank you.

And there are no further questions at this time. I’d like to turn the call back over to Mr. Crowley for any additional or closing comments.

No, that’s it. Thank you, everyone, for participating in this conference call, and we look forward to keeping you updated on development, and hope this was a very helpful summary for everyone. Have a great night. Take care.

And again, that does conclude today’s conference call. Again, we’d like to thank you for your participation and you make disconnect at this time.